{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-023796","form_type":"8-K","ticker":"CVRX","cik":"0001235912","company_name":"CVRx, Inc.","filed_at":"2022-02-15T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.697698+00:00","generated_at":"2026-06-27T07:52:07.023417+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CVRx posts Q4 revenue $3.7M (+75% YoY); FY2021 revenue $13.0M; guides FY2022 rev $20-23M","bullets":["Q4 2021 revenue $3.7M, up 75% YoY; US HF revenue $2.7M, up 345%.","Full year 2021 revenue $13.0M, up 115% YoY; net loss $43.1M ($4.16 per share).","Guides FY2022 total revenue $20-23M; Q1 2022 revenue $3.6-4.0M; gross margin 74-76%.","Received FDA approval for new IPG in Dec 2021; expects MRI labeling and new programmer approvals in H1 2022.","Fully repaid $20M loan in Nov 2021; cash $142.1M at year-end."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-023796","json":"https://secwatch.observer/filing/0001104659-22-023796.json","markdown":"https://secwatch.observer/filing/0001104659-22-023796.md","text":"https://secwatch.observer/filing/0001104659-22-023796.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1235912/000110465922023796/0001104659-22-023796-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1235912/000110465922023796/tm226604d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T07:52:07.023417+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}